Illumina Expands Proteomics Play with $350M SomaLogic Buy
Event summary
- Illumina completed its $350M acquisition of SomaLogic on January 30, 2026, with up to $75M in performance-based milestones and royalties.
- The deal expands Illumina's multiomics portfolio by integrating SomaLogic's proteomics technology with Illumina's NGS ecosystem and DRAGEN software.
- Illumina aims to leverage the acquisition to accelerate drug discovery and healthcare insights through scalable protein analysis.
- The acquisition builds on a 2021 co-development partnership between the two companies.
The big picture
Illumina's acquisition of SomaLogic is a strategic move to strengthen its position in the multiomics market, combining proteomics with its existing genomics capabilities. This deal comes as the proteomics market continues to grow, driven by the need for deeper insights into protein function and interactions to accelerate drug discovery and improve healthcare outcomes. The acquisition positions Illumina to compete more effectively in the expanding proteomics space, leveraging its global reach and product innovation.
What we're watching
- Integration Challenges
- Whether Illumina can successfully integrate SomaLogic's technology and operations into its existing portfolio without disrupting customer relationships.
- Market Penetration
- The pace at which Illumina can increase customer access to SomaLogic's technologies and service offerings in the expanding proteomics market.
- Financial Impact
- How the acquisition will affect Illumina's financial performance, with details to be discussed in the upcoming earnings call on February 5, 2026.
Related topics